10 minute read
May 16, 2024
AstraZeneca’s Oral, Selective CDK2 Inhibitor for the Treatment of CDK4/6 Inhibitor-Resistant Cancers and CCNE1-Amplified Tumors
AZD8421
oral selective CDK2 inhibitor Ph. I/II for advanced or metastatic solid tumors optimization from literature compounds AACR San Diego 2024, “New Drugs on the Horizon” AstraZeneca, Waltham, MA
Loading...
